GlassScriptPhysician profile
Syed W Moazzem
NPI 1972777415
$4,477.35
in general payments reported to CMS, 2019-2025
28 companies · $265 in 2025
The $265 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,015 · 2020: $138 · 2021: $514 · 2022: $1,330 · 2023: $974 · 2024: $241 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,395 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,395.33 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,126.30 | 2019-2025 | |
| Amgen INC. | $805.78 | 2019-2025 | Evenity, Enbrel, Prolia |
| Janssen Biotech, INC. | $608.65 | 2021-2025 | Tremfya, Stelara, Simponi |
| Novartis Pharmaceuticals Corporation | $284.54 | 2019-2025 | |
| Ucb, INC. | $279.39 | 2020-2025 | Cimzia, Bimzelx |
| Celgene Corporation | $244.60 | 2019 | |
| Lilly USA, LLC | $177.30 | 2019-2025 | Taltz |
| Mallinckrodt Hospital Products INC. | $172.62 | 2020-2024 | Acthar |
| Regeneron Healthcare Solutions, INC. | $121.60 | 2019 | |
| Horizon Therapeutics Plc | $120.97 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $87.72 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $85.63 | 2021-2023 | Saphnelo, Tezspire |
| Glaxosmithkline, LLC. | $55.30 | 2019-2022 | |
| Novo Nordisk INC | $52.91 | 2019-2021 | |
| Genentech USA, INC. | $29.94 | 2024-2025 | Actemra |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $23.40 | 2024 | Coolseal Generator |
| Abbott Laboratories | $20.99 | 2020 | |
| Aurinia Pharma U.S., INC. | $20.66 | 2023 | Lupkynis |
| Pacira Pharmaceuticals Incorporated | $19.91 | 2023 | Zilretta, Iovera, Exparel |
| E.R. Squibb & Sons, L.L.C. | $19.45 | 2021 | |
| Convatec INC. | $18.29 | 2024 | |
| Bioventus LLC | $17.45 | 2021 | |
| Kerecis Limited | $16.66 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Pfizer INC. | $15.75 | 2021 | |
| Ani Pharmaceuticals, INC. | $14.77 | 2022 | |
| Seqirus USA INC | $14.03 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.70 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $11.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Moazzem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.